Using Pedometers for the Assessment and Enhancement of Mobility in Gynaecological and Oncological Patients Following Surgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tel Aviv, Israel, 64239
- Recruiting
- Tel Aviv Medical Center
-
Contact:
- Aviad Cohen, MD
- Phone Number: 972-547333450
- Email: co.aviad@gmail.com
-
Principal Investigator:
- eli shprecher, prof.
-
Contact:
- Ido Laskov, MD
- Email: idolaskov@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients following gynecology and gynecology oncology surgery Consent to participation No medical recommendation for bed rest and limited mobility
Exclusion Criteria:
Refusal to participate Medical recommendation to limit mobility
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental: Feedback
Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge.
During this period, they will recieve feedback regrding the number of steps taken by them at the end of each day
|
Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
|
|
No Intervention: No Intervention: Control
Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge.
During this period, they will recieve no feedback regrding the number of steps taken by them.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of steps per day during the hospitalization period
Time Frame: Up to 1 week
|
umber of steps taken by patient as recirded by pedometer
|
Up to 1 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with complication following surgery
Time Frame: Up to 1 week
|
infectious ( wound), blood product transfusion
|
Up to 1 week
|
|
Number of analgesic doses
Time Frame: Up to 1 week
|
Number of doses of analgesics consumed by patient
|
Up to 1 week
|
|
Length of hospitalization
Time Frame: Up to 4 week
|
Duration of hospitalization following surgery
|
Up to 4 week
|
|
Number of thromboembolic events
Time Frame: Up to 4 week
|
hromboembolic events, including deep vein thrombosis and pulmonary emboli
|
Up to 4 week
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 0689-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.